Final answer:
The prescriber erred by not specifying the type of Novolin insulin, while the nurse incorrectly administered Novolin N (NPH) without confirmation. Clear prescriptions and confirmations can prevent such errors, and recombinant DNA technology allows the production of human insulin, benefitting diabetics.
Step-by-step explanation:
The prescriber ordered Novolin insulin 20 units subcut stat for a client. The prescriber's error, in this case, was not specifying the type of Novolin insulin, as there are different types, such as Novolin R (regular, short-acting) and Novolin N (NPH, intermediate-acting). On the other hand, the nurse's error was assuming and administering Novolin N (NPH) without clarification on which specific type of Novolin was to be given 'stat,' which usually indicates a need for rapid action, typically associated with short-acting insulins.
To prevent such errors, clearer communication and prescription orders are needed. The prescriber should clearly indicate the type of insulin, and the nurse should confirm any unclear orders before administration. Also, standardized protocols and double-checking mechanisms can reduce medication errors.
Today, the technology that allows diabetic patients to purchase human insulin from a pharmacist is recombinant DNA technology. This is a significant benefit over previous methods because it ensures a consistent and safe supply of insulin that is identical to human insulin, thus reducing the risk of allergic reactions and other complications associated with animal-derived insulins.